Hereditary ovarian cancer: beyond the usual suspects.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Gynecologic Oncology

• Publication date

  2012-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2011.12.415PMID 22264603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Mutations of the SLX4 gene in Fanconi anemia

  2011cited by this paper
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

  2011cited by this paper
• Germline mutations in RAD51D confer susceptibility to ovarian cancer

  2011cited by this paper
• Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.

  2011cited by this paper
• SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype

  2011cited by this paper
• Mutations in BRIP1 confer high risk of ovarian cancer

  2011cited by this paper
• Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.

  2011cited by this paper
• Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.

  2011cited by this paper
• Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

  2011cited by this paper
• Genetic Counseling Considerations in the Evaluation of Families for Lynch Syndrome—A Review

  2011cited by this paper
• Susceptibility pathways in Fanconi's anemia and breast cancer.

  2010cited by this paper
• Common variants at 19p13 are associated with susceptibility to ovarian cancer

  2010cited by this paper
• Genetic heterogeneity in human disease.

  2010cited by this paper
• Advances in understanding cancer genomes through second-generation sequencing

  2010cited by this paper
• A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24

  2010cited by this paper
• A novel germline PALB2 deletion in Polish breast and ovarian cancer patients

  2010cited by this paper
• Mutation of the RAD51C gene in a Fanconi anemia–like disorder

  2010cited by this paper
• Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

  2010cited by this paper
• Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome

  2009cited by this paper
• Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

  2009cited by this paper
• The genetic and molecular basis of Fanconi anemia.

  2009cited by this paper
• Fanconi anemia and its diagnosis.

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Common genetic variation and human traits.

  2009cited by this paper
• Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.

  2009cited by this paper
• A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2

  2009cited by this paper
• Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

  2008cited by this paper
• PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

  2007cited by this paper
• Breast Cancer Risk Is Associated with the Genes Encoding the DNA Double-Strand Break Repair Mre11/Rad50/Nbs1 Complex

  2007cited by this paper
• ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles

  2006cited by this paper
• Molecular pathogenesis of Fanconi anemia: recent progress.

  2006cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

  2006cited by this paper
• Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

  2006cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.

  2005cited by this paper
• Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

  2004cited by this paper
• Histopathology, FIGO Stage, and BRCA Mutation Status of Ovarian Cancers from the Gilda Radner Familial Ovarian Cancer Registry

  2004cited by this paper
• Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers

  2004cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel.

  2003cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.

  2003cited by this paper
• Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study.

  2002cited by this paper
• Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations

  2002cited by this paper
• Biallelic Inactivation of BRCA2 in Fanconi Anemia

  2002cited by this paper
• Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families

  2002cited by this paper
• The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.

  2001cited by this paper
• Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

  2001cited by this paper
• BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

  2000cited by this paper
• Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions.

  1999cited by this paper
• Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

  1998cited by this paper
• Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.

  1997cited by this paper
• Cancer risk associated with germline DNA mismatch repair gene mutations.

  1997cited by this paper
• A polymorphic stop codon in BRCA2

  1996cited by this paper
• The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

  1996cited by this paper
• Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

  1996cited by this paper
• The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals

  1995cited by this paper
• Cancer predisposition of ataxia-telangiectasia heterozygotes.

  1990cited by this paper
• Traité des tumeurs

  year unknowncited by this paper

• Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses.

  2025cites this paper
• Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.

  2025cites this paper
• Serous tubal intraepithelial carcinoma—looking into the earliest events of ovarian cancer development

  2025cites this paper
• Salpingectomy for ectopic pregnancy reduces ovarian cancer risk—a nationwide study

  2024cites this paper
• Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

  2024cites this paper
• The Molecular Detection of Germline Mutations in the BRCA1 and BRCA2 Genes Associated with Breast and Ovarian Cancer in a Romanian Cohort of 616 Patients

  2024cites this paper
• The prognostic and predictive value of homologous recombination deficiency status in patients with advanced stage epithelial ovarian carcinoma after first-line platinum-based chemotherapy

  2024cites this paper
• Uptake of Cancer Genetic Services for Chatbot vs Standard-of-Care Delivery Models

  2024cites this paper
• Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer

  2023cites this paper
• Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

  2023cites this paper
• Improved detection of homologous recombination deficiency in Chinese patients with ovarian cancer: a novel non‐exonic single‐nucleotide polymorphism‐based next‐generation sequencing panel

  2023cites this paper
• Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches

  2023cites this paper
• Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.

  2023cites this paper
• A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis

  2023cites this paper
• Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles

  2023cites this paper
• Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy

  2022cites this paper
• Can Automated Alerts in the Electronic Health Record Encourage Referrals for Genetic Counseling and Testing Among Patients at High Risk for Hereditary Cancer Syndromes?

  2022cites this paper
• Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain

  2022cites this paper
• Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis

  2022cites this paper
• Examining interprofessional collaboration in oncogenetic service delivery models for hereditary cancers: a scoping review protocol

  2022cites this paper
• Breast and Gynecologic Tumors

  2021cites this paper
• European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer.

  2021cites this paper
• Metabolic risk factors of ovarian cancer: a review

  2021cites this paper
• Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients.

  2021cites this paper
• Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

  2021influential citation
• Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.

  2021cites this paper
• Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial

  2021cites this paper
• Fertility preservation in patients with BRCA mutations or Lynch syndrome

  2021cites this paper
• MLH1 Gene

  2020cites this paper
• Genetic Factors

  2020cites this paper
• BRCA2 Gene

  2020cites this paper
• MSH2 Gene

  2020cites this paper
• BRCA1 Gene

  2020cites this paper
• Multi-Omics Approaches to Study Signaling Pathways

  2020cites this paper
• Genetics and the Gynecologic Patient

  2020cites this paper
• Second Primary Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers after Breast Cancer Diagnosis: Korea Central Cancer Registry

  2020cites this paper
• Treatment of epithelial ovarian cancer

  2020cites this paper
• The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.

  2020cites this paper
• Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes

  2020cites this paper
• Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicin

  2020cites this paper
• Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion

  2020cites this paper
• Cancer of the Breast

  2020cites this paper
• Aportación de la secuenciación masiva de nueva generación en el diagnóstico del síndrome de cáncer de mama y ovario hereditario mediante el uso de un panel de genes

  2019cites this paper
• Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer

  2019cites this paper
• Clinicoepidemilogical Correlation of BRCA 1 and 2 Mutations in Carcinoma Ovary - an Indian Perspective

  2019cites this paper
• Hereditary Risk for Cancer

  2019cites this paper
• Genetic Counseling for Pancreatic Cancer

  2019cites this paper
• BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group

  2019cites this paper
• Genetic polymorphism of MTHFR C 677 T contributes to the risk of ovarian cancer : a meta-analysis

  2019cites this paper
• Cellular Localization of RAD51D Mutant Proteins and the Application of Art to Increase Scientific Literacy in America

  2019influential citation
• Integrative Bioinformatics Approaches to Map Potential Novel Genes and Pathways Involved in Ovarian Cancer

  2019cites this paper
• Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation.

  2019cites this paper
• Epidemiologic Relationship Between Obesity and Ovarian Cancer

  2018cites this paper
• Management of newly diagnosed or recurrent ovarian cancer.

  2018cites this paper
• Aktuelle Aspekte in der BRCA-Diagnostik: Konsequenzen für Prävention und Therapie

  2018cites this paper
• Germline pathogenic variants identified in women with ovarian tumors.

  2018cites this paper
• Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.

  2018cites this paper
• Mutational and Functional Analysis of FANCB as a Candidate Gene for Sporadic Head and Neck Squamous Cell Carcinomas.

  2018cites this paper
• Ovarian Cancer Genetics: Subtypes and Risk Factors

  2018cites this paper
• Chapter 2 Epidemiologic Relationship Between Obesity and Ovarian Cancer

  2018influential citation
• Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy.

  2017cites this paper
• Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

  2017cites this paper
• Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer

  2017cites this paper
• Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature

  2017cites this paper
• PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers

  2017cites this paper
• Frontline therapy of ovarian cancer: trials and tribulations

  2017cites this paper
• Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.

  2017cites this paper
• Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling

  2017cites this paper
• [Hereditary breast and ovarian cancer].

  2017cites this paper
• Role and clinical application of next-generation sequencing (NGS) for ovarian cancer

  2017cites this paper
• Massive parallel sequencing of solid tumours – challenges and opportunities for pathologists

  2017cites this paper
• Inherited mutations in DNA repair genes and cancer risk.

  2017cites this paper
• Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.

  2017cites this paper
• The Role of rad51c on the Fanconi Anemia Pathway in Zebrafish

  2017influential citation
• CT and MRI in Ovarian Carcinoma

  2017cites this paper
• Molecular Basis of PARP Inhibition and Future Opportunities in Ovarian Cancer Therapy

  2017cites this paper
• Cáncer de ovario. De la detección a la prevención

  2017cites this paper
• Prophylactic Oophorectomy for Patients with Germline BRCA Mutations

  2017cites this paper
• Germline Testing for Predisposition to Breast/Ovarian Cancer Should Only be Offered to Selected Patients with Epithelial Ovarian Cancer

  2017cites this paper
• Identification of licofelone through three-dimensional cell culture drug screening as a repurposed agent able to reverse drug resistant and cancer stem cell-like subpopulations in ovarian cancer

  2017cites this paper
• Multi-disciplinary summit on genetics services for with cancers: A Society of White Paper.

  2017cites this paper
• OVARIAN CANCER

  2016cites this paper
• Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

  2016cites this paper
• Germline mutations of the DNA repair pathways in uterine serous carcinoma.

  2016cites this paper
• Evaluation of laboratory perspectives on hereditary cancer panels

  2016cites this paper
• Individualized Novel Therapies for Patients with Tumor Suppressor Genes BRCA1 and BRCA2 Mutated Epithelial Ovarian Cancer

  2016cites this paper
• Contribution des effets ciblés et non ciblés en radioimmunothérapie alpha et Auger de carcinoses péritonéales

  2016cites this paper
• The Shu complex is a conserved regulator of Rad51 filament formation

  2016cites this paper
• The genetic prediction of risk for gynecologic cancers.

  2016cites this paper
• Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

  2016cites this paper
• Next-Generation Sequencing: Role in Gynecologic Cancers.

  2016cites this paper
• Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer

  2016cites this paper
• An Overview of the Management of Gynaecological Cancers

  2016cites this paper
• Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.

  2015cites this paper
• Breast Cancer Genetics and Risk Assessment

  2015cites this paper
• Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic

  2015cites this paper
• Ovary Cancer: Surgical Techniques and Innovative Treatments

  2015cites this paper
• Overview of Gynecologic Cancers

  2015cites this paper
• MTHFR A1298C polymorphism and ovarian cancer risk: a meta-analysis.

  2015cites this paper
• Impact of the 2014 NCCN guidelines for genetic testing on an academic gynecologic oncology practice

  2015cites this paper